BRPI0918178B8 - anticorpos monoclonais para tratamento de câncer - Google Patents

anticorpos monoclonais para tratamento de câncer

Info

Publication number
BRPI0918178B8
BRPI0918178B8 BRPI0918178A BRPI0918178A BRPI0918178B8 BR PI0918178 B8 BRPI0918178 B8 BR PI0918178B8 BR PI0918178 A BRPI0918178 A BR PI0918178A BR PI0918178 A BRPI0918178 A BR PI0918178A BR PI0918178 B8 BRPI0918178 B8 BR PI0918178B8
Authority
BR
Brazil
Prior art keywords
cancer
monoclonal antibodies
cancer treatment
metastatic
lung
Prior art date
Application number
BRPI0918178A
Other languages
English (en)
Portuguese (pt)
Inventor
Koslowski Michael
Mitnacht-Kraus Rita
Sahin Ugur
Türeci Özlem
Original Assignee
Ganymed Pharmaceuticals Ag
Ganymed Pharmaceuticals Gmbh
Univ Mainz Johannes Gutenberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals Ag, Ganymed Pharmaceuticals Gmbh, Univ Mainz Johannes Gutenberg filed Critical Ganymed Pharmaceuticals Ag
Publication of BRPI0918178A2 publication Critical patent/BRPI0918178A2/pt
Publication of BRPI0918178A8 publication Critical patent/BRPI0918178A8/pt
Publication of BRPI0918178B1 publication Critical patent/BRPI0918178B1/pt
Publication of BRPI0918178B8 publication Critical patent/BRPI0918178B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0918178A 2008-09-16 2009-09-16 anticorpos monoclonais para tratamento de câncer BRPI0918178B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US9745308P 2008-09-16 2008-09-16
EP08016277A EP2166021A1 (en) 2008-09-16 2008-09-16 Monoclonal antibodies for treatment of cancer
EP08016277.9 2008-09-16
US61/097,453 2008-09-16
PCT/EP2009/006704 WO2010031551A2 (en) 2008-09-16 2009-09-16 Monoclonal antibodies for treatment of cancer

Publications (4)

Publication Number Publication Date
BRPI0918178A2 BRPI0918178A2 (pt) 2015-12-01
BRPI0918178A8 BRPI0918178A8 (pt) 2020-05-19
BRPI0918178B1 BRPI0918178B1 (pt) 2021-04-06
BRPI0918178B8 true BRPI0918178B8 (pt) 2021-05-25

Family

ID=40589589

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918178A BRPI0918178B8 (pt) 2008-09-16 2009-09-16 anticorpos monoclonais para tratamento de câncer

Country Status (27)

Country Link
US (1) US8946388B2 (enExample)
EP (3) EP2166021A1 (enExample)
JP (1) JP2012502938A (enExample)
KR (1) KR101818741B1 (enExample)
CN (3) CN105753988A (enExample)
AU (1) AU2009294896B2 (enExample)
BR (1) BRPI0918178B8 (enExample)
CA (1) CA2732594C (enExample)
CY (1) CY1119956T1 (enExample)
DK (1) DK2342234T3 (enExample)
ES (1) ES2659718T3 (enExample)
HK (1) HK1253579A1 (enExample)
HR (1) HRP20180262T1 (enExample)
HU (1) HUE036477T2 (enExample)
IL (2) IL211010A (enExample)
LT (1) LT2342234T (enExample)
MX (2) MX2011002856A (enExample)
NO (1) NO2342234T3 (enExample)
NZ (2) NZ596490A (enExample)
PL (1) PL2342234T3 (enExample)
PT (1) PT2342234T (enExample)
RS (1) RS56937B1 (enExample)
SI (1) SI2342234T1 (enExample)
SM (1) SMT201800079T1 (enExample)
TR (1) TR201802090T4 (enExample)
WO (1) WO2010031551A2 (enExample)
ZA (1) ZA201100835B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
PT2187965T (pt) 2007-08-17 2020-01-17 Purdue Research Foundation Conjugados ligando-ligante de ligação a psma e métodos para utilização
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
WO2012098407A1 (en) * 2011-01-19 2012-07-26 Cantargia Ab Anti - il1rap antibodies and their use for treating human
US20130236890A1 (en) * 2012-03-08 2013-09-12 HI-STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine gGmbH Novel method for analyzing circulating tumor cells of a patient for the presence of metastasis-initiating cells
KR101471253B1 (ko) * 2012-10-29 2014-12-10 인제대학교 산학협력단 암 표적 항체 및 이를 포함하는 암 예방 또는 치료용 조성물
JP6892218B2 (ja) 2012-11-15 2021-06-23 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 薬物送達結合体およびｐｓｍａ発現細胞によって引き起こされる疾患の治療方法
EP3415489A1 (en) 2013-10-18 2018-12-19 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
BR112016010927A2 (pt) 2013-11-14 2017-08-08 Endocyte Inc Conjugado de fórmula
EP3143045A1 (en) * 2014-05-12 2017-03-22 Numab AG Novel multispecific molecules and novel treatment methods based on such multispecific molecules
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US10167334B2 (en) * 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
JP6895946B2 (ja) * 2015-07-14 2021-06-30 メディミューン，エルエルシー 癌の治療用組成物及び方法
JP6951825B2 (ja) 2015-09-04 2021-10-20 ザ スクリプス リサーチ インスティテュート インスリン免疫グロブリン融合タンパク質
CA3007031A1 (en) * 2015-12-01 2017-06-08 Genmab B.V. Anti-death receptor antibodies and methods of use thereof
EP4124343A1 (en) * 2016-10-20 2023-02-01 I-Mab Biopharma US Limited Novel cd47 monoclonal antibodies and uses thereof
US20200087390A1 (en) 2016-12-21 2020-03-19 Amgen Inc. Anti-tnf alpha antibody formulations
CN106632661A (zh) * 2017-01-10 2017-05-10 天津东亚生物技术有限公司 利用hla‑g分子及其抗原片段制备预防肿瘤和病毒病的广谱疫苗及其应用
CN108124445B (zh) * 2017-03-15 2021-05-04 苏州银河生物医药有限公司 Ctla4抗体、其药物组合物及其用途
CN107556369A (zh) * 2017-08-23 2018-01-09 天津国际生物医药联合研究院 一种抗原肽和用于检测肿瘤细胞的抗体制备方法及其应用
US12208102B2 (en) 2018-04-17 2025-01-28 Endocyte, Inc. Methods of treating cancer
CN109402064B (zh) * 2018-11-05 2021-05-14 湖南省肿瘤医院 杂交瘤细胞株及其产生的单克隆抗体和应用
CN120097930A (zh) 2019-05-20 2025-06-06 因多塞特股份有限公司 制备psma缀合物的方法
KR102266418B1 (ko) * 2019-07-30 2021-06-16 한국생명공학연구원 영여자 추출물을 유효성분으로 함유하는 전립선 질환의 예방 및 치료용 조성물

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
US5744585A (en) 1995-03-16 1998-04-28 Medenica; Rajko D. Human monoclonal antibody against lung carcinoma
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US20020065394A1 (en) * 1998-03-18 2002-05-30 Kenneth Jacobs Secreted proteins and polynucleotides encoding them
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
WO2002012437A2 (en) 2000-08-03 2002-02-14 Schooten Wim Van Production of humanized antibodies in transgenic animals
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2003075014A2 (en) 2002-03-06 2003-09-12 Oxford Glycosciences (Uk) Ltd Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
ATE540978T1 (de) 2002-10-17 2012-01-15 Genmab As Humane monoklonale antikörper gegen cd20
ATE533857T1 (de) 2003-01-17 2011-12-15 Univ Hong Kong Chinese Zirkulierende mrna als diagnostische marker für erkankungen die mit einer schwangerschaft zusammenhängen
US20050255114A1 (en) 2003-04-07 2005-11-17 Nuvelo, Inc. Methods and diagnosis for the treatment of preeclampsia
CN1663603A (zh) 2004-03-02 2005-09-07 北京大学 一种肿瘤－胎盘抗原蛋白及其dna在肿瘤治疗中的应用
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
SG173444A1 (en) 2009-02-20 2011-09-29 Ganymed Pharmaceuticals Ag Methods and compositions for diagnosis and treatment of cancer
EP2221063A1 (en) 2009-02-20 2010-08-25 Ganymed Pharmaceuticals AG Methods and compositions for diagnosis and treatment of cancer

Also Published As

Publication number Publication date
CY1119956T1 (el) 2018-12-12
SMT201800079T1 (it) 2018-03-08
KR101818741B1 (ko) 2018-01-15
IL211010A (en) 2015-11-30
CN102164963A (zh) 2011-08-24
TR201802090T4 (tr) 2018-03-21
IL242204A0 (en) 2015-11-30
IL211010A0 (en) 2011-04-28
PL2342234T3 (pl) 2018-07-31
AU2009294896A1 (en) 2010-03-25
BRPI0918178B1 (pt) 2021-04-06
MX357010B (es) 2018-06-22
HUE036477T2 (hu) 2018-07-30
NZ596490A (en) 2013-05-31
HRP20180262T1 (hr) 2018-03-23
IL242204B (en) 2020-09-30
RS56937B1 (sr) 2018-05-31
CN102164963B (zh) 2015-07-29
AU2009294896B2 (en) 2015-04-30
CA2732594C (en) 2019-05-28
EP2342234A2 (en) 2011-07-13
US20110223182A1 (en) 2011-09-15
BRPI0918178A2 (pt) 2015-12-01
WO2010031551A3 (en) 2010-09-16
PT2342234T (pt) 2018-02-21
WO2010031551A2 (en) 2010-03-25
JP2012502938A (ja) 2012-02-02
MX2011002856A (es) 2011-06-28
CN104628858B (zh) 2018-11-16
LT2342234T (lt) 2018-03-12
SI2342234T1 (en) 2018-04-30
CN105753988A (zh) 2016-07-13
EP2342234B1 (en) 2017-11-15
US8946388B2 (en) 2015-02-03
BRPI0918178A8 (pt) 2020-05-19
ES2659718T3 (es) 2018-03-19
NO2342234T3 (enExample) 2018-04-14
KR20110055699A (ko) 2011-05-25
ZA201100835B (en) 2014-04-30
HK1253579A1 (en) 2019-06-21
NZ591004A (en) 2012-03-30
DK2342234T3 (en) 2018-02-26
EP2166021A1 (en) 2010-03-24
EP3312198A1 (en) 2018-04-25
CN104628858A (zh) 2015-05-20
CA2732594A1 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
BRPI0918178B8 (pt) anticorpos monoclonais para tratamento de câncer
MX372766B (es) Anticuerpos que se unen a cldn6.
MX385874B (es) Anticuerpos especificos para claudina 6 (cldn6).
MX2020011782A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2009012906A (es) Anticuerpos monoclonales contra claudin-18 para tratamiento de cancer.
HK1208151A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2007133822A8 (en) Gitr antibodies for the treatment of cancer
CY1117031T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
MX2009009816A (es) Anticuerpos monoclonales para el tratamiento del cancer.
UA117121C2 (uk) Біспецифічне антитіло до egfr/с-мет
EA201390328A1 (ru) Новые антигенсвязывающие белки
EP1893196A4 (en) DIARYLHYDANTOIN CONNECTIONS
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
EP2582727A4 (en) ANTIBODIES TO ENDOPLASMINE AND ITS USE
EA201690599A1 (ru) Конъюгированные антитела против ly75 для лечения рака
EA201391423A1 (ru) Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
EP4556071A3 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
NZ607472A (en) Treatment for neoplastic diseases
WO2014198919A3 (en) Tumor marker, monoclonal antibodies and methods of use thereof
EP2630498A4 (en) PROGNOSTIC BIOMARKERS IN PATIENTS WITH EGG CANCER
NZ589795A (en) Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
Walsh Re: Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European Randomized Study of Screening for Prostate Cancer-Rotterdam after 11 years of follow-up
IL207478A0 (en) Monoclonal antibodies for tumor treatment

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/09/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25D Requested change of name of applicant approved

Owner name: JOHANNES GUTENBERG- UNIVERSITAET MAINZ (DE) ; GANYMED PHARMACEUTICALS GMBH (DE)

B25G Requested change of headquarter approved

Owner name: JOHANNES GUTENBERG- UNIVERSITAET MAINZ (DE) ; GANYMED PHARMACEUTICALS GMBH (DE)

B25A Requested transfer of rights approved

Owner name: JOHANNES GUTENBERG- UNIVERSITAET MAINZ (DE) ; ASTELLAS PHARMA INC. (JP)

B25A Requested transfer of rights approved

Owner name: ASTELLAS PHARMA INC. (JP) ; TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAET MAINZ GEMEINNUETZIGE GMBH (DE)

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 14A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2740 DE 11-07-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.